Ares-Serono To Submit Rebif Neutralizing Antibody Study in 1999 - EPAR
Executive Summary
Ares-Serono is planning to submit a report to European Union authorities in late 1999 describing results of a two-year extension study on the effect of neutralizing antibodies on the efficacy of Rebif, the company's recombinant interferon beta-1a multiple sclerosis therapy, according to the European Public Assessment Report for the product.